menu
    • menu
    [{"orgOrder":0,"company":"Ora, Inc","sponsor":"OKYO Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"OK-101","moa":"Chemerin receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Oculis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Stuart Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ST-100","moa":"Helical collagen","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Stuart Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vezocolmitide","moa":"Helical collagen","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Stuart Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Stuart Therapeutics"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Stuart Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Vezocolmitide","moa":"Helical collagen","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Palatin Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PL9643","moa":"MCR","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Palatin Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Palatin Technologies"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Azura Ophthalmics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"LENZ Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aceclidine Hydrochloride","moa":"muscarinic receptor agonists","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RCI001","moa":"RAC1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Oculis","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Licaminlimab","moa":"TNF","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Allgenesis Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AG-80308","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"BRM421","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Ora, Inc \/ Ora, Inc"},{"orgOrder":0,"company":"Ora, Inc","sponsor":"Neuracle Genetics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"NG101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Ora, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ora, Inc \/ Ora, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Ora, Inc \/ Ora, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by Ora, Inc

    Menu

    Ora, Inc

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RCI001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of RCI001 Ophthalmic Solution Safety & Efficacy in Subjects with Dry Eye

                            Details : RCI001 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 16, 2025

                            Lead Product(s) : RCI001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AZR-MD-001

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Azura Ophthalmics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease ...

                            Details : AZR-MD-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : AZR-MD-001

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Azura Ophthalmics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vezocolmitide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Stuart Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Stuart Therapeutics Announces First Patient, First Visit in Its Phase 3 Clinical Trial of Vezocolmitide for Dr...

                            Details : ST-100 (vezocolmitide) is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen. It is under phase 3 clinical development for the treatment of Dry Eye D...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 29, 2023

                            Lead Product(s) : Vezocolmitide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Stuart Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vezocolmitide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Stuart Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects ...

                            Details : Vezocolmitide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 21, 2023

                            Lead Product(s) : Vezocolmitide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Stuart Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Oculis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

                            Details : Dexamethasone is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Endophthalmitis.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            November 13, 2023

                            Lead Product(s) : Dexamethasone

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Oculis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NG101

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Recipient : Neuracle Genetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

                            Details : NG101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 09, 2023

                            Lead Product(s) : NG101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Neuracle Genetics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Recipient : LENZ Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Pr...

                            Details : Aceclidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Eye Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 07, 2023

                            Lead Product(s) : Aceclidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Recipient : LENZ Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Licaminlimab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Recipient : Oculis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

                            Details : Licaminlimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 09, 2023

                            Lead Product(s) : Licaminlimab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Recipient : Oculis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OK-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Recipient : OKYO Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

                            Details : OK-101 is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 08, 2023

                            Lead Product(s) : OK-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Recipient : OKYO Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Ora, Inc

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aceclidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Safety Study for the Treatment of Presbyopia Subjects

                            Details : Aceclidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Presbyopia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2023

                            Lead Product(s) : Aceclidine Hydrochloride

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : LENZ Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth